Our Pipeline
We have a rapidly expanding and advancing pipeline of novel monotherapy and combination product candidates that have shown a consistent safety profile and increasing evidence of efficacy surrogates such as biomarkers.
Stage
NG-347
Three transgenes:
producing membrane bound CD80 and secreted MIP1α and IFNα
T-cell attraction
and activation
NG-796A
Three transgenes:
producing IL-12, IL-15 and a chemokine
T-cell and
NK Cell
activation
NG-XXX
Novel transgene combinations
Variety of mechanisms targeted
Product
Transgene
Payload
Principal
Mechanism
NG-350A
Two transgenes:
producing a secreted CD40 agonist monoclonal antibody
NG-641
Four transgenes:
producing an anti-FAP bispecific plus cytokines/ chemokines
CD40 Agonism
Phase 1
Phase 2
Phase 3
Research
IND
Enabling
Commercial Rights
Anti-
Stromal
